Migraine is one of the most common neurological diseases manifested by headache attacks. Calcitonin-gene related peptide (CGRP) plays a key role in the pathophysiology of migraine. The release of CGRP during a migraine attack leads to cranial vasodilation and neurogenic inflammation. As a result, the sensory fibres of the trigeminal nerve become activated and the transmission of pain impulses to the brain is modulated. Due to the wide representation of CGRP receptors in the brain, the calcitonin-gene related peptide is an actively studied target in studies of antimigraine drugs. This review presents the mechanisms of action, a description of the structure, receptors of the calcitonin gene-related peptide in the pathophysiology of migraine and demonstrates new therapeutic options related to CGRP.
Molybdenum cofactor deficiency type B (MOCODB; #252160) is an autosomal recessive metabolic disorder that has only been described in 37 affected patients. In this report, we describe the presence of an in-frame homozygous variant (c.471_477delTTTAAAAinsG) in the MOCS2 gene in an affected child, diagnosed with Ohtahara syndrome according to the clinical manifestations. The analysis of the three-dimensional structure of the protein and the amino acid substitutions suggested the pathogenicity of this mutation. To prevent transmitting this mutation to the next generation, we used preimplantation genetic testing for the monogenic disorders (PGT-M) protocol to select MOCS2 gene mutant-free embryos for transfer in an in vitro fertilization (IVF) program. As a result, a healthy child was born. Interestingly, both parents of the proband shared an identical mitochondrial (mt) DNA control region, assuming their close relationship and thus suggesting that both copies of the nuclear rare variant c.471_477delTTTAAAAinsG may have been transmitted from the same female ancestor. Our estimation of the a priori probability of meeting individuals with the same mtDNA haplotype confirms the assumption of a possible distant maternal relationship among the proband’s direct relatives.
21 November 2025 in Movement Disorders Clinical Practice
Синдром Миллса (СМ)— идиопатический, медленно прогрессирующий восходящий спастический гемипарез. Некоторыми авторами рассматривается как односторонний вариант прогрессирующего бокового склероза. Ввиду редкости заболевания и медленного клинического течения представляет несомненный интерес клинический случай, описываемый в статье. Также обсуждаются диагностические критерии СМ.
Multisystem atrophy (MSA) is a sporadic progressive neurodegenerative disease that is manifested by a combination of autonomic and motor dysfunctions: parkinsonism, cerebellar ataxia, pyramidal syndrome, etc. Given the complexity of the diagnosis, the clinical polymorphism and the ignorance of neurologists about this disease, patients are often followed up by doctors of other profile or are observed with an incorrect diagnosis. There are two main MCA phenotypes – predominant cerebellar ataxia (MSA-C) and predominant parkinsonism (MSA-P), which are determined by the localization of the affected structures and the dominance of certain clinical symptoms. This article presents three clinical cases with different subtypes of MSA. Despite the difference in clinical manifestations, all patients was diagnosed with clinically established MSA. The features of the collection of complaints and anamnesis are described, the analysis of the neurological status and characteristic neuroimaging markers that can help in the differential diagnosis of this rare disease is carried out.